A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function

Inclusion Criteria: All Participants:

• Women not of childbearing potential may participate and include those who areinfertile due to surgical sterilization (hysterectomy, bilateral oophorectomy,bilateral salpingectomy or tubal ligation), congenital anomaly such as mullerianagenesis; or postmenopausal

• Are between the body mass index (BMI) of 18.0 and 42.0 kilograms per meter squared (kg/m²), inclusive, at screening Healthy Participants:

• Healthy females as determined by medical history, physical examination, and otherscreening procedures, with normal liver function Participants with Impaired Liver Function:

• Females with chronic mild, moderate and severe liver impairment, assessed byChild-Pugh scoring

• Have diagnosis of chronic hepatic impairment (>6 months), with no clinicallysignificant changes within 90 days prior to study drug administration.

Exclusion Criteria:

• Women of childbearing potential are excluded from the study.
• Have known allergies to imlunestrant or related compounds
• Have a history of alcoholism or drug/chemical abuse within 2 years prior to check-in
• Have received blood products within 2 months prior to check-in
• Have evidence of HIV infection and/or positive human HIV antibodies
• Have used or intend to use medications that are strong inhibiters or inducers ofcytochrome P450 (CYP)3A4
• Who smoke more than 10 cigarettes or use the equivalent tobacco, smoking-cessationproducts, nicotine-containing products, or e-cigarettes (nicotine and non-nicotine)per day.
• Have a history or presence of cardiovascular (eg, symptomatic bradycardia with restingheart rate of <60 beats per minute), respiratory, renal, gastrointestinal, endocrine,hematological, or neurological disorders capable of significantly altering theabsorption, metabolism, or elimination of drugs